Literature DB >> 22648968

Risk of retinoblastoma is associated with a maternal polymorphism in dihydrofolatereductase (DHFR) and prenatal folic acid intake.

Manuela A Orjuela1, Lourdes Cabrera-Muñoz, Ligi Paul, Marco A Ramirez-Ortiz, Xinhua Liu, Jia Chen, Fabiola Mejia-Rodriguez, Aurora Medina-Sanson, Silvia Diaz-Carreño, Ida H Suen, Jacob Selhub, M Veronica Ponce-Castañeda.   

Abstract

BACKGROUND: The incidence of unilateral retinoblastoma varies globally, suggesting possible environmental contributors to disease incidence. Maternal intake of naturally occurring folate from vegetables during pregnancy is associated inversely with the risk of retinoblastoma in offspring.
METHODS: The authors used a case-control study design to examine the association between retinoblastoma risk and maternal variations in the folate-metabolizing genes methylenetetrahydrofolate reductase (MTHFR) (a cytosine-to-thymine substitution at nucleotide 677 [MTHFR677C→T]; reference single nucleotide polymorphism rs1801133) and dihydrofolate reductase (DHFR) (a 19-base-pair deletion of intron 1a [DHFR19bpdel]; rs70991108). In central Mexico, 103 mothers of children with newly diagnosed unilateral retinoblastoma were enrolled in an institutional review board-approved study along with a control group of 97 mothers who had healthy children. Mothers were interviewed regarding perinatal characteristics, including use of prenatal vitamin supplements, and gave peripheral blood samples, which were used for polymerase chain reaction-based genotyping of rs1801133 and rs70991108.
RESULTS: The risk of having a child with unilateral retinoblastoma was associated with maternal homozygosity for DHFR19bpdel (odds ratio, 3.78; 95% confidence interval, 1.89-7.55; P = .0002), even after controlling for the child's DHFR19bpdel genotype (odds ratio, 2.81; 95% confidence interval, 1.32-5.99; P = .0073). In a subgroup of 167 mothers with data on prenatal intake of supplements containing folic acid (a synthetic form of folate), DHFR19bpdel-associated risk was elevated significantly only among those who reported taking folic acid supplements. Maternal MTHFR genotype was unrelated to the risk of having a child with retinoblastoma.
CONCLUSIONS: Maternal homozygosity for a polymorphism in the DHFR gene necessary for converting synthetic folic acid into biologic folate was associated with an increased risk for retinoblastoma. Prenatal ingestion of synthetic folic acid supplements may be associated with increased risk for early childhood carcinogenesis in a genetically susceptible subset of the population.
Copyright © 2012 American Cancer Society.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22648968      PMCID: PMC3434235          DOI: 10.1002/cncr.27621

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  32 in total

1.  Use of nutritional supplements among Mexican women and the estimated impact on dietary intakes below the EAR and above the UL.

Authors:  Fabiola Mejía-Rodríguez; Daniela Sotres-Alvarez; Lynnette M Neufeld; Armando García-Guerra; Christine Hotz
Journal:  J Am Coll Nutr       Date:  2007-02       Impact factor: 3.169

2.  High dietary folate supplementation affects gestational development and dietary protein utilization in rats.

Authors:  M Achón; L Reyes; E Alonso-Aperte; N Ubeda; G Varela-Moreiras
Journal:  J Nutr       Date:  1999-06       Impact factor: 4.798

3.  Annual report to the nation on the status of cancer, 1975-2003, featuring cancer among U.S. Hispanic/Latino populations.

Authors:  Holly L Howe; Xiaocheng Wu; Lynn A G Ries; Vilma Cokkinides; Faruque Ahmed; Ahmedin Jemal; Barry Miller; Melanie Williams; Elizabeth Ward; Phyllis A Wingo; Amelie Ramirez; Brenda K Edwards
Journal:  Cancer       Date:  2006-10-15       Impact factor: 6.860

4.  Folate intake, alcohol use, and postmenopausal breast cancer risk in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial.

Authors:  Rachael Z Stolzenberg-Solomon; Shih-Chen Chang; Michael F Leitzmann; Karen A Johnson; Christine Johnson; Saundra S Buys; Robert N Hoover; Regina G Ziegler
Journal:  Am J Clin Nutr       Date:  2006-04       Impact factor: 7.045

5.  Fruit and vegetable intake during pregnancy and risk for development of sporadic retinoblastoma.

Authors:  Manuela A Orjuela; Lina Titievsky; Xinhua Liu; Marco Ramirez-Ortiz; Veronica Ponce-Castaneda; Evelia Lecona; Evelyn Molina; Katherine Beaverson; David H Abramson; Nancy E Mueller
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2005-06       Impact factor: 4.254

6.  Folic acid and risk of prostate cancer: results from a randomized clinical trial.

Authors:  Jane C Figueiredo; Maria V Grau; Robert W Haile; Robert S Sandler; Robert W Summers; Robert S Bresalier; Carol A Burke; Gail E McKeown-Eyssen; John A Baron
Journal:  J Natl Cancer Inst       Date:  2009-03-10       Impact factor: 13.506

7.  A cost-effectiveness analysis of folic acid fortification policy in the United States.

Authors:  Tanya Gk Bentley; Milton C Weinstein; Walter C Willett; Karen M Kuntz
Journal:  Public Health Nutr       Date:  2008-07-01       Impact factor: 4.022

8.  Folic acid for the prevention of colorectal adenomas: a randomized clinical trial.

Authors:  Bernard F Cole; John A Baron; Robert S Sandler; Robert W Haile; Dennis J Ahnen; Robert S Bresalier; Gail McKeown-Eyssen; Robert W Summers; Richard I Rothstein; Carol A Burke; Dale C Snover; Timothy R Church; John I Allen; Douglas J Robertson; Gerald J Beck; John H Bond; Tim Byers; Jack S Mandel; Leila A Mott; Loretta H Pearson; Elizabeth L Barry; Judy R Rees; Norman Marcon; Fred Saibil; Per Magne Ueland; E Robert Greenberg
Journal:  JAMA       Date:  2007-06-06       Impact factor: 56.272

9.  A functional 19-base pair deletion polymorphism of dihydrofolate reductase (DHFR) and risk of breast cancer in multivitamin users.

Authors:  Xinran Xu; Marilie D Gammon; James G Wetmur; Manlong Rao; Mia M Gaudet; Susan L Teitelbaum; Julie A Britton; Alfred I Neugut; Regina M Santella; Jia Chen
Journal:  Am J Clin Nutr       Date:  2007-04       Impact factor: 7.045

10.  A 19-base pair deletion polymorphism in dihydrofolate reductase is associated with increased unmetabolized folic acid in plasma and decreased red blood cell folate.

Authors:  Renee D Kalmbach; Silvina F Choumenkovitch; Aron P Troen; Paul F Jacques; Ralph D'Agostino; Jacob Selhub
Journal:  J Nutr       Date:  2008-12       Impact factor: 4.798

View more
  13 in total

1.  Folate.

Authors:  Yen-Ming Chan; Regan Bailey; Deborah L O'Connor
Journal:  Adv Nutr       Date:  2013-01-01       Impact factor: 8.701

2.  Maternal diet during pregnancy and unilateral retinoblastoma.

Authors:  Christina Lombardi; Arupa Ganguly; Greta R Bunin; Saeedeh Azary; Vivian Alfonso; Beate Ritz; Julia E Heck
Journal:  Cancer Causes Control       Date:  2014-12-27       Impact factor: 2.506

3.  Diagnostic delay and sociodemographic predictors of stage at diagnosis and mortality in unilateral and bilateral retinoblastoma.

Authors:  Marco A Ramírez-Ortiz; M Veronica Ponce-Castañeda; M Lourdes Cabrera-Muñoz; Aurora Medina-Sansón; Xinhua Liu; Manuela A Orjuela
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2014-02-12       Impact factor: 4.254

4.  Influence of dihydrofolate reductase gene polymorphisms rs408626 (-317A>G) and rs442767 (-680C>A) on the outcome of methotrexate-based maintenance therapy in South Indian patients with acute lymphoblastic leukemia.

Authors:  Sunitha Kodidela; Suresh Chandra Pradhan; Biswajit Dubashi; Debdatta Basu
Journal:  Eur J Clin Pharmacol       Date:  2015-09-03       Impact factor: 2.953

Review 5.  Folic acid supplementation in pregnancy and implications in health and disease.

Authors:  Subit Barua; Salomon Kuizon; Mohammed A Junaid
Journal:  J Biomed Sci       Date:  2014-08-19       Impact factor: 8.410

6.  A case-control study of sporadic retinoblastoma in relation to maternal health conditions and reproductive factors: a report from the Children's Oncology group.

Authors:  Julia E Heck; Negar Omidakhsh; Saeedeh Azary; Beate Ritz; Ondine S von Ehrenstein; Greta R Bunin; Arupa Ganguly
Journal:  BMC Cancer       Date:  2015-10-19       Impact factor: 4.430

7.  miRNome landscape analysis reveals a 30 miRNA core in retinoblastoma.

Authors:  Blanca Elena Castro-Magdonel; Manuela Orjuela; Javier Camacho; Adda Jeanette García-Chéquer; Lourdes Cabrera-Muñoz; Stanislaw Sadowinski-Pine; Noé Durán-Figueroa; María de Jesús Orozco-Romero; Ana Claudia Velázquez-Wong; Adriana Hernández-Ángeles; Claudia Hernández-Galván; Citlali Lara-Molina; M Verónica Ponce-Castañeda
Journal:  BMC Cancer       Date:  2017-07-01       Impact factor: 4.430

8.  Maternal Haplotypes in DHFR Promoter and MTHFR Gene in Tuning Childhood Acute Lymphoblastic Leukemia Onset-Latency: Genetic/Epigenetic Mother/Child Dyad Study (GEMCDS).

Authors:  Veronica Tisato; Paola Muggeo; Tracy Lupiano; Giovanna Longo; Maria Luisa Serino; Massimo Grassi; Ermanno Arcamone; Paola Secchiero; Giorgio Zauli; Nicola Santoro; Donato Gemmati
Journal:  Genes (Basel)       Date:  2019-08-22       Impact factor: 4.096

9.  The 19-bp deletion polymorphism of dihydrofolate reductase (DHFR) and nonsyndromic cleft lip with or without cleft palate: evidence for a protective role.

Authors:  Firoozeh Rafighdoost; Amir Rafighdoost; Houshang Rafighdoost; Mohammad-Ayoob Rigi-Ladez; Mohammad Hashemi; Ebrahim Eskandari-Nasab
Journal:  J Appl Oral Sci       Date:  2015 May-Jun       Impact factor: 2.698

10.  Circulating miRNome detection analysis reveals 537 miRNAS in plasma, 625 in extracellular vesicles and a discriminant plasma signature of 19 miRNAs in children with retinoblastoma from which 14 are also detected in corresponding primary tumors.

Authors:  Blanca Elena Castro-Magdonel; Manuela Orjuela; Diana E Alvarez-Suarez; Javier Camacho; Lourdes Cabrera-Muñoz; Stanislaw Sadowinski-Pine; Aurora Medina-Sanson; Citlali Lara-Molina; Daphne García-Vega; Yolanda Vázquez; Noé Durán-Figueroa; María de Jesús Orozco-Romero; Adriana Hernández-Ángeles; M Verónica Ponce-Castañeda
Journal:  PLoS One       Date:  2020-04-14       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.